ARTICLE | Company News
Apeiron Biologics, EUSA Pharma deal
October 10, 2016 7:00 AM UTC
Apeiron granted EUSA exclusive, worldwide rights to commercialize pediatric neuroblastoma candidate Isqette dinutuximab beta ( APN311). The chimeric mAb against ganglioside GD2 (GD2) is under review ...